2. Search Result
Search Result
Results for "

Osteoclastogenesis Inhibitor

" in MedChemExpress (MCE) Product Catalog:

48

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

25

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N3188
    Niloticin

    		Akt NF-κB Infection
    Niloticin, tetracyclic triterpenoid compound, is a osteoclastogenesis inhibitor. Niloticin shows anti-viral, antioxidative, and mosquitocidal activities. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways .
    Niloticin
  • HY-N2119
    Sciadopitysin
    1 Publications Verification

    		 TNF Receptor NF-κB Inflammation/Immunology
    Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba . Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 .
    Sciadopitysin
  • HY-12212
    Omaveloxolone
    Maximum Cited Publications
    19 Publications Verification

    RTA 408

    		 Keap1-Nrf2 STING Apoptosis Inflammation/Immunology Cancer
    Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.
    Omaveloxolone
  • HY-110318
    VUF11207 fumarate
    2 Publications Verification

    		 CXCR Inflammation/Immunology Cancer
    VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
    VUF11207 fumarate
  • HY-N11775
    Eudebeiolide B

    Plebeiolide D

    		 NF-κB Akt Nuclear Factor of activated T Cells (NFAT) Phosphatase Metabolic Disease
    Eudebeiolide B is a compound that can be isolated from Salvia plebeia R. Br. Eudebeiolide B inhibits osteoclastogenesis by regulating RANKL-induced NF-κB, c-Fos and calcium signaling. Eudebeiolide B can be used for osteoclast-related diseases research .
    Eudebeiolide B
  • HY-N10838
    Ajudecunoid A

    		Others Others
    Ajudecunoid A is nature product that could be isolated from Ajuga decumbens. Ajudecunoid A inhibits RANKL-Induced osteoclastogenesis .
    Ajudecunoid A
  • HY-N10076
    Ganomycin I

    		HMG-CoA Reductase (HMGCR) Glycosidase HIV Protease Infection Metabolic Disease
    Ganomycin I is a dual inhibitor of α-Glucosidase and HMG-CoA reductase. Ganomycin I can also inhibits HIV protease. Ganomycin I exhibits anti-diabetic and anti-osteoclastogenesis effects .
    Ganomycin I
  • HY-111266
    Halenaquinone

    		PI3K Apoptosis Inflammation/Immunology Cancer
    Halenaquinone is a phosphatidylinositol 3-kinase inhibitor and can be isolated from the marine sponge Petrosia alfiani. Halenaquinone inhibits RANKL-induced osteoclastogenesis, and induces cell apoptosis in PC12 cells .
    Halenaquinone
  • HY-N12604
    Penicisteck acid F

    		NF-κB Others
    Penicisteck acid F (Compound 2) is a Marine derived tanzanic acid derivative that is a NF-κB inhibitor. Penicisteck acid F inhibits osteoclast expression by decreasing RANKL-induced IκBα degradation, NF-κB p65 nuclear translocation, NFATc1 activation and nuclear translocation, and related mRNA expression. Penicisteck acid F can be used in osteoporosis research .
    Penicisteck acid F
  • HY-169857
    AS2690168 (freebase)

    		RANKL/RANK Others
    AS2690168 freebase is an orally active RANKL signal transduction inhibitor which suppresses RANKL-induced osteoclastogenesis of RAW264 cells. AS2690168 can be utilized in research related to pathological osteolysis .
    AS2690168 (freebase)
  • HY-169857A
    AS2690168 hydrochloride

    		RANKL/RANK Others
    AS2690168 hydrochloride is an orally active RANKL signal transduction inhibitor which suppresses RANKL-induced osteoclastogenesis of RAW264 cells. AS2690168 can be utilized in research related to pathological osteolysis .
    AS2690168 hydrochloride
  • HY-N12740
    Napyradiomycin B4

    		MEK ERK Others
    Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced MEK-ERK signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis .
    Napyradiomycin B4
  • HY-153675
    BCPA

    		PIN1 Metabolic Disease
    BCPA is a Pin1 regulator without cytotoxicity. BCPA attenuates the reduction of Pin1 protein to inhibit receptor activator of RANKL-induced osteoclastogenesis. BCPA regulates osteoclast activation, used to osteoporosis research .
    BCPA
  • HY-N12555
    6,6′-Didemethyl-7-methyl dragonbloodin A2

    		Others Others
    6,6′-Didemethyl-7-methyl dragonbloodin A2 is isolated from the dragon’s blood of Daemonorops draco fruits and is a osteoclastogenesis inhibitor with IC50 value of 36.8 μM[1].
    6,6′-Didemethyl-7-methyl dragonbloodin A2
  • HY-120140
    Ganoderic acid DM
    1 Publications Verification

    		 Apoptosis PI3K Metabolic Disease Inflammation/Immunology Cancer
    Ganoderic acid DM, a natural triterpenoid isolated from Ganoderma lucidum, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Ganoderic acid DM as a specific inhibitor of osteoclastogenesis .
    Ganoderic acid DM
  • HY-155342
    A3373

    		Phospholipase Inflammation/Immunology
    A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis .
    A3373
  • HY-158098
    FGFR1 inhibitor-11

    		FGFR Metabolic Disease
    FGFR1 inhibitor-11 (compound 5g) binds to FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor-11 has oral bioactivity .
    FGFR1 inhibitor-11
  • HY-161848
    TCP-MP-CA

    		Histone Demethylase Cancer
    TCP-MP-CA (compound 11a) is an inhibitor of LSD1 demethylation enzymatic via binding to LSD1/CoREST complex. TCP-MP-CA exhibits an inhibitory effect on osteoclastogenesis, with an IC50 value of 0.14 µM .
    TCP-MP-CA
  • HY-N2119R
    Sciadopitysin (Standard)

    		TNF Receptor Reference Standards NF-κB Inflammation/Immunology
    Sciadopitysin (Standard) is the analytical standard of Sciadopitysin. This product is intended for research and analytical applications. Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba . Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 .
    Sciadopitysin (Standard)
  • HY-N0257
    Epimedin A
    2 Publications Verification

    		 PI3K Akt NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Heme Oxygenase (HO) SOD Caspase Interleukin Related Metabolic Disease Inflammation/Immunology
    Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases .
    Epimedin A
  • HY-162847
    S24–14

    		Others Metabolic Disease
    S24–14 is a potent antiosteoporosis agent. S24–14 inhibits osteoclastogenesis with an IC50 value of 0.40 µM. S24–14 induces osteoblast differentiation. S24–14 suppresses bone loss .
    S24–14
  • HY-N13219
    Angelica Extract

    		Others Metabolic Disease
    Angelica Extract is an angelica extract, and its components include: Ligustilide. Angelica Extract can effectively inhibit the differentiation of osteoclasts, regulate osteoclastogenesis and/or bone loss. Angelica Extract has the potential to be used in the study of various bone diseases caused by excessive bone resorption. .
    Angelica Extract
  • HY-158311
    Anti-osteoporosis agent-8

    		RANKL/RANK p38 MAPK NF-κB Endocrinology
    Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC50 is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model .
    Anti-osteoporosis agent-8
  • HY-118482
    Sauristolactam

    Saurolactam

    		 Others Neurological Disease
    Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells . Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation .
    Sauristolactam
  • HY-124478
    Ethyl gentisate

    Ethyl 2,5-dihydroxybenzoate

    		 Phosphatase Metabolic Disease
    Ethyl gentisate (Ethyl 2,5-dihydroxybenzoate) is a dual modulator for cell differentiation, that enhances the osteogenic differentiation of human mesenchymal stem cells (hMSCs) and alkaline phosphatase activity, inhibits RANKL-activated osteoclastogenesis in RAW264.7 cells, and balances the bone remodeling process .
    Ethyl gentisate
  • HY-W641445
    ELP-004

    		TRP Channel Inflammation/Immunology
    ELP-004 is a TRPC channel inhibitor and inhibtis TRPC channel-mediated Ca 2+ entry. ELP-004 is an osteoclast inhibitor and inhibits osteoclast differentiation. ELP-004 inhibits basal Ca 2+ and related NFATc1 translocation in inflammatory osteoclastogenesis. ELP-004 reduces bone erosion in a mouse model of rheumatoid arthritis .
    ELP-004
  • HY-N1419
    Vaccarin

    		AMPK Akt ERK p38 MAPK NF-κB Nuclear Factor of activated T Cells (NFAT) JNK Cardiovascular Disease Metabolic Disease
    Vaccarin is an orally active flavonoid glycoside with multiple biological functions. Vaccarin promotes neovascularization by activating AKT and ERK. Vaccarin activates the AMPK signaling pathway to improve insulin resistance and steatosis. Vaccarin is a MAPK, NF-κB, and NFAT inhibitor, effectively blocking RANKL-induced osteoclastogenesis .
    Vaccarin
  • HY-161869
    LSD1-IN-32

    		Histone Methyltransferase Metabolic Disease
    LSD1-IN-32 (compound 11e) is a potent LSD1 inhibitor with an IC50 value of 0.99 µM. LSD1-IN-32 inhibits RANKL-induced osteoclastogenesis, bone resorption and F-actin belt formation. LSD1-IN-32 has the potential for the research of osteoporosis .
    LSD1-IN-32
  • HY-149852
    Anti-osteoporosis agent-3

    		Others Inflammation/Immunology
    Anti-osteoporosis agent-3 (Compound 11), a PMSA derivative, is an anti-osteoporosis agent. Anti-osteoporosis agent-3 inhibits osteoclastogenesis with an IC50 value of 322.9 nM in vitro. Anti-osteoporosis agent-3 also blocks the formation of F-action belts and bone resorption .
    Anti-osteoporosis agent-3
  • HY-124958
    NDMC101

    		NF-κB Dipeptidyl Peptidase Metabolic Disease Inflammation/Immunology
    NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al .
    NDMC101
  • HY-113556
    Sappanone A
    4 Publications Verification

    		 Phosphodiesterase (PDE) NF-κB Keap1-Nrf2 Reactive Oxygen Species (ROS) TNF Receptor Nuclear Factor of activated T Cells (NFAT) Akt ERK p38 MAPK NO Synthase Interleukin Related COX JNK Cardiovascular Disease Inflammation/Immunology
    Sappanone A is an orally active homoisoflavone found in sappan L. Sappanone A is a PDE4 and NF-κB inhibitor with anti-inflammatory and antioxidant effect. Sappanone A induces HO-1 expression through activation of Nrf2 pathway. Sappanone A also inhibits RANKL-induced osteoclastogenesis. Sappanone A has great potential in the research of inflammation-related and cardiovascular .
    Sappanone A
  • HY-155960
    SH491

    		Others Inflammation/Immunology
    SH491 (Compound 33) is an antiosteoporosis agent. SH491 inhibits RANKL-induced osteoclast differentiation on bone-marrow-derived monocytes (BMMs) (IC50: 11.8 nM). SH491 inhibits the expression of osteoclastogenesis-related marker genes (TRAP, CTSK, MMP-9, and ATPase v0d2) and proteins (TRAP, CTSK, MMP-9) .
    SH491
  • HY-N0257R
    Epimedin A (Standard)

    		Reference Standards PI3K Akt NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Heme Oxygenase (HO) SOD Caspase Interleukin Related Metabolic Disease Inflammation/Immunology
    Epimedin A (Standard) is the analytical standard of Epimedin A (HY-N0257). This product is intended for research and analytical applications. Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases .
    Epimedin A (Standard)
  • HY-N14126
    Chlovalicin

    		Others Cancer
    Chlovalicin is found in the strain of Sporothrix sp. FO-4649. In the presence of 0.2 U/mL IL-6, Chlovalicin inhibits the growth of L6-dependent MH60 cells with lC50 of 7.5 μM. Chlovalicin also inhibits the growth of B16 melanoma cells with lC50 of 38 μM. Chlovalicin also displays inhibitory activity on osteoclastogenesis .
    Chlovalicin
  • HY-N6052
    (+)-Medicarpin

    		Estrogen Receptor/ERR Cancer
    (+)-Medicarpin, a pterocarpan, is a type of isoflavonoid isolated from several medicinal plant species with various biological effects, including Sophora japonica, Zollernia paraensis and Platymiscium yucatamun, Machaerium aristulatum, Platymiscium floribundum, and so on. (+)-Medicarpin potently inhibits osteoclastogenesis and promotes bone healing and increases bone mass by osteoblast differentiation with estrogen receptor (ER) β-mediated osteogenic action .
    (+)-Medicarpin
  • HY-W438351
    1,3-Dibenzyl-5-fluorouracil

    		RANKL/RANK Metabolic Disease
    1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor of osteoclastogenesis. 1,3-Dibenzyl-5-fluorouracil inhibits the expression of osteoclast markers by downregulating the receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) signaling pathways. 1,3-Dibenzyl-5-fluorouracil can be used in the study of metabolic bone diseases .
    1,3-Dibenzyl-5-fluorouracil
  • HY-149472
    Anti-osteoporosis agent-4

    		NF-κB PI3K Inflammation/Immunology
    Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC50 value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation .
    Anti-osteoporosis agent-4
  • HY-162280
    PROTAC BTK Degrader-9

    		PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk Cancer
    PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca 2+-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .
    PROTAC BTK Degrader-9
  • HY-N12561
    Pestanoid A

    		ERK p38 MAPK JNK Others
    Pestanoid A is a rearranged pimarane diterpenoid osteoclastogenesis inhibitor with an IC50 of 4.2 μM. Pestanoid A can be isolated from the marine mesophotic zone chalinidae sponge-associated fungus, Pestalotiopsis sp. NBUF145. Pestanoid A inhibits the receptor activator of NF-kB ligand-induced MAPK and NF-κB signaling by suppressing the phosphorylation of ERK1/2-JNK1/2-p38 MAPKs and NF-κB nuclear translocation. Pestanoid A can be used for the study of osteoporosis .
    Pestanoid A
  • HY-145491
    Resolvin D5

    		ERK NF-κB Inflammation/Immunology
    Resolvin D5 is a prolytic mediator (SPM) with anti-inflammatory activity derived from oxidized lipids DHA. Resolvin D5 inhibits Th17 cell differentiation and promotes regulatory T cell differentiation, and inhibits CD4+ T cell proliferation. Resolvin D5 attenuates osteoclast differentiation and interferes with osteoclastogenesis. Resolvin D5 also regulates ERK phosphorylation and nuclear translocation of NF-kappaB. Resolvin D5 could be used in rheumatoid arthritis research .
    Resolvin D5
  • HY-P991365
    DS-1501

    		Transmembrane Glycoprotein Endocrinology
    DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    DS-1501
  • HY-N1746
    (2S)-2'-Methoxykurarinone

    2'-O-Methylkurarinone

    		 RANKL/RANK Metabolic Disease Inflammation/Immunology Cancer
    (2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .
    (2S)-2'-Methoxykurarinone
  • HY-13777C
    Zoledronate disodium

    CGP 42446 disodium; CGP42446A disodium; ZOL 446 disodium

    		 Apoptosis Cancer
    Zoledronate (CGP 42446) disodium is a potent bisphosphonate that effectively inhibits osteoclastogenesis, reducing bone turnover and stabilizing the bone matrix. Zoledronate disodium has demonstrated notable effectiveness in managing Paget's disease of bone by suppressing metabolic activity and alleviating bone pain. Zoledronate disodium is being investigated in the ongoing ZiPP trial for its potential to prevent disease progression in patients with Paget's disease. Zoledronate disodium also exhibits diverse anti-tumor effects in osteosarcoma, further highlighting its multifunctional therapeutic applications.
    Zoledronate disodium
  • HY-N9736
    6,4'-Dihydroxy-7-methoxyflavanone

    		Calcineurin Infection Neurological Disease Inflammation/Immunology
    6,4'-Dihydroxy-7-methoxyflavanone, a flavonoid, is a nature product that could be isolated from Heartwood Dalbergia odorifera. 6,4'-Dihydroxy-7-methoxyflavanone inhibits receptor activators of nuclear factor kappa-B ligand (RANKL) induced osteoclastogenesis. 6,4'-Dihydroxy-7-methoxyflavanone has antioxidant, anti-inflammatory and neuroprotective effects. 6,4'-Dihydroxy-7-methoxyflavanone can be used in research of osteoporosis .
    6,4'-Dihydroxy-7-methoxyflavanone
  • HY-N2157
    Pteryxin
    1 Publications Verification

    (+)-Pteryxin

    		 Cholinesterase (ChE) NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Reactive Oxygen Species (ROS) Nuclear Factor of activated T Cells (NFAT) p38 MAPK Neurological Disease Metabolic Disease Inflammation/Immunology
    Pteryxin ((+)-Pteryxin) is an orally active multi-target inhibitor that targets NF-κB, MAPK, NLRP3 inflammasome, and Nrf2/ARE pathways. Pteryxin is also a BChE inhibitor (IC50=12.96 μg/mL) with a low inhibitory efficiency on AChE. Pteryxin inhibits the Ca 2+-calcineurin-NFATc1 pathway by blocking NF-κB/MAPK signaling, inhibiting NLRP3 inflammasome activation, and reducing ROS generation, and activates Nrf2-mediated antioxidant enzyme expression. Pteryxin has anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin can be used in the study of inflammatory diseases, osteoporosis, diabetes, and Alzheimer's disease .
    Pteryxin
  • HY-15001G
    Stemregenin 1

    SR1

    		 Aryl Hydrocarbon Receptor Cancer
    Stemregenin 1 (SR1) (GMP) is a GMP-grade Stemregenin 1 (HY-15001). GMP-grade small molecules can be used as adjuvants in cell therapy. Stemregenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with an IC50 of 127 nM. Stemregenin 1 (GMP) can competitively bind to AhR and inhibit its nuclear translocation, inhibiting osteoclastogenesis and promoting hematopoietic progenitor cell expansion by blocking the AhR-c-src-NF-κB/p-ERK MAPK-NFATc1 signaling pathway. Stemregenin 1 (GMP) can be used for the treatment of osteoporosis, in vitro expansion of hematopoietic stem cells, and the study of the mechanism of bone metabolic diseases .
    Stemregenin 1
  • HY-N0507
    Rosavin

    		TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis .
    Rosavin
  • HY-N0507R
    Rosavin (Standard)

    		Reference Standards TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    Rosavin (Standard) is the analytical standard of Rosavin. This product is intended for research and analytical applications. Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis .
    Rosavin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: